Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
According to the recently published report 'Toll Like Receptor 8 - Drugs In Development, 2022'; Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 35 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes.
Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It controls host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.
The report 'Toll Like Receptor 8 - Drugs In Development, 2022' outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 11, 7, 12 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecule, respectively.
Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Solid Tumor, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Hepatitis B, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), Bladder Cancer, Gastric Cancer, Autoimmune Disorders, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Cervical Cancer, Cutaneous Lupus Erythematosus, Fibrosis, Gastroesophageal (GE) Junction Carcinomas, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Merkel Cell Carcinoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Nasopharyngeal Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Prostate Cancer, Renal Cell Carcinoma, Sarcomas, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer), Unspecified Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Anal Cancer, Arthritis, Chondrosarcoma, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Colon Cancer, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Pneumonia, Cutaneous T-Cell Lymphoma, Endometrial Cancer, Esophageal Cancer, Ewing Sarcoma, Head And Neck Cancer, Hepatocellular Carcinoma, Hypopharyngeal Cancer, Inflammation, Kaposi Sarcoma, Laryngeal Cancer, Leiomyosarcoma, Leukemia, Medullary Thyroid Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Mycosis Fungoides, Neuroendocrine Tumors, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteoarthritis, Osteosarcoma, Pancreatic Cancer, Penile Cancer, Pleomorphic Liposarcoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Subacute Cutaneous Lupus Erythematosus (SCLE), Synovial Sarcoma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Companies Mentioned
Companies Mentioned
Altimmune Inc
Ambrx Biopharma Inc
Ascendis Pharma AS
Avidea Technologies Inc
Bolt Biotherapeutics Inc
Bristol-Myers Squibb Co
Curebiotech Inc
Curevac NV
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
IngenoVax LLC
Janus Biotherapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
Merck KGaA
Nektar Therapeutics
Novartis AG
Resolve Therapeutics LLC
Seven and Eight Biopharmaceuticals Corp
Seven and Eight Biopharmaceuticals Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Zhimeng Biopharma Inc
Silverback Therapeutics Inc
UroGen Pharma Ltd
Vaccex Inc
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook